Can S. boulardii replace an antifungal?

No. The linked evidence tested probiotics as an add-on to conventional treatment, not instead of it.

Does taking a yeast make a yeast infection worse?

S. boulardii is a different, non-pathogenic species that competes with Candida rather than adding to it.

What dose is typical?

250 mg twice daily, roughly 5 billion CFU per capsule, is the common adjunctive dose.

Can I take it with antibiotics?

Yes. It is a yeast, so antibiotics do not kill it, which is one of its main practical advantages.

Anyone immunocompromised, critically ill, or with a central venous catheter, because of documented fungaemia cases.

Outcome

Moderate Evidence

Effectiveness 3/5

Saccharomyces Boulardii for Candida Control

S. boulardii is the best-supported option for limiting Candida overgrowth, particularly around antibiotic courses.

Overview

Saccharomyces boulardii is a yeast used as a probiotic, which makes it an unusual choice against another yeast. The logic is competitive: it occupies the same niches Candida species exploit, without being susceptible to the antifungals used to clear them.

The evidence linked here is about probiotics as adjuncts to conventional antifungal treatment, not as replacements for it. That distinction matters more than any dosing detail on this page.

Verdict

Likely effective

A Cochrane review of probiotics in vulvovaginal candidiasis found higher short-term cure rates and fewer one-month relapses when probiotics were added to conventional treatment, but rated all the evidence low or very low certainty.

How It Works

S. boulardii secretes capric and caprylic acid, which inhibit the yeast-to-hyphae transition that Candida albicans depends on to invade tissue. In cell culture it also reduces Candida adhesion to epithelial surfaces and dampens the inflammatory response the infection provokes.

Being a yeast rather than a bacterium, it survives antibiotic courses intact. That is why it is the classic choice when antibiotic use has disturbed the flora that ordinarily keeps Candida in check, though this rationale is mechanistic rather than demonstrated in the linked review.

Dosing & Protocol

Doses are expressed either in milligrams of lyophilised yeast or in colony-forming units, with 250 mg corresponding to roughly 5 billion CFU. Clinical use typically runs 500 to 1000 mg daily, taken alongside rather than instead of a prescribed antifungal.

Scenario	Dose	Form	Timing
General maintenance	250 mg once daily	Lyophilised capsule	Any time, with food
Adjunct during antifungal treatment	250 mg twice daily	Lyophilised capsule	Spaced through the day
During and after antibiotics	500 mg twice daily	Lyophilised capsule	Continue 2 weeks past the course
Upper range in general use	1000 mg daily	Divided doses	Split morning and evening

1
Confirm the diagnosis first· Before starting
Symptoms attributed to Candida are frequently something else. Treat a confirmed infection, not an assumption.
2
Take the prescribed antifungal· As prescribed
The linked review tested probiotics as an add-on to conventional treatment, which is the only supported way to use them here.
3
Add 250 mg twice daily· Throughout treatment
Unlike bacterial probiotics, S. boulardii is unaffected by antibiotics and can be taken concurrently.
4
Continue for two to four weeks after· Weeks 1 to 4 post-treatment
The relapse benefit in the linked review was measured at one month, which argues for continuing past symptom resolution.
5
Stop and reassess if symptoms persist· At 4 weeks
Recurrent confirmed candidiasis warrants medical review, not an escalating probiotic dose.

Evidence

One study is linked to this pairing: the 2017 Cochrane review of probiotics for vulvovaginal candidiasis in non-pregnant women, pooling 1,656 participants. Probiotics used as adjuncts increased short-term clinical and mycological cure and reduced one-month relapse.

Best linked evidence: Cochrane systematic review, 1,656 participants
Linked result: Higher short-term clinical and mycological cure; lower one-month relapse
Population: Non-pregnant women with vulvovaginal candidiasis
Main limitation: All findings graded low or very low certainty; mixed probiotic species
Certainty: Low, and specific to adjunctive use alongside antifungal treatment

Studies linked to this pairing.

Probiotics for vulvovaginal candidiasis in non-pregnant women

Score: 8/10

2017

systematic_review

n=1656

Xie HY, Feng D, Wei DM

Probiotic adjuncts, including yeast and lactobacillus preparations, showed low-certainty benefit in candidiasis.

View source

Safety

S. boulardii is well tolerated by people with intact immunity, and mild bloating or gas in the first few days is the usual complaint. The important exception is serious: because it is a live yeast, it can enter the bloodstream in vulnerable patients.

Reported effects

Bloating and gas early on

Constipation in some users

Fungaemia risk if immunocompromised

Risk with central venous catheters

Avoid in critical illness

Do not use if you are immunocompromised or have a central line

Cases of S. boulardii fungaemia are documented in immunosuppressed and critically ill patients, and in those with indwelling central venous catheters. This is a firm contraindication, not a precaution.

Interactions & Conflicts

The one pharmacological interaction that matters is with antifungal drugs. S. boulardii is a yeast, so systemic antifungals will kill it, which defeats the point of taking the two together at the same moment.

Interacts with	Severity	Mechanism	Action
Systemic antifungals such as fluconazole	moderate	The drug kills the probiotic yeast	Separate doses by several hours
Immunosuppressant therapy	high	Impaired defence against live yeast	Avoid
Central venous catheters	high	Documented route to fungaemia	Avoid
Antibiotics	low	None; the yeast is not antibiotic-sensitive	Can be taken concurrently
MAO inhibitors	low	Theoretical tyramine content of yeast preparations	Mention to your prescriber

References

The claims on this page about clinical outcomes come from the linked Cochrane review; the mechanistic account of caprylic acid and hyphal inhibition comes from laboratory work and is labelled as such.

Xie HY et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev. 2017

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.